Expression of CKS2 in Hepatocellular Carcinoma: Correlation with Survival Outcomes and Immune Microenvironment
Renhou Zhi,Pengfei Hao,Weibin Li,Haoliang Zhao
DOI: https://doi.org/10.2147/jhc.s427624
2023-10-10
Journal of Hepatocellular Carcinoma
Abstract:Renhou Zhi, Pengfei Hao, Weibin Li, Haoliang Zhao Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People's Republic of China Correspondence: Haoliang Zhao, Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan, 030032, People's Republic of China, Tel +86 138 0340 0588, Email Purpose: Cyclin-dependent kinase regulatory subunit 2 (CKS2) has an important function in regulating cancer progression and cell cycle. This research aims to ascertain how CKS2 plays its part through multi-omics analyses, to reveal its relationship with the immune microenvironment in hepatocellular carcinoma (HCC). Material and Methods: Multiple databases were used to determine the transcriptional data of CKS2, epigenetic changes, and effects thereof upon the prognosis of HCC patients. The biological functions of CKS2 in HCC were expounded by functional enrichment analysis. TIMER, GSEA, TIP, and online single-cell sequencing databases were adopted for revealing correlations of CKS2 expression with infiltration of immune cells, immunomodulators, immunity cycle, and immune markers in the immune microenvironment of HCC. In addition, qRT-PCR and Western blot were used to validate gene expression in tissues from HCC patients. Results: Open database analysis confirmed that CKS2 is highly expressed in HCC and that it is related to poor prognosis in HCC patients. Aberrant methylation levels of the two methylation sites of CKS2 in HCC contributed to its high expression and were correlated significantly with survival. The CKS2 expression was positively correlated with most immunomodulators and infiltration levels for B and CD8+T cells, dendritic cells, and macrophages, especially exhausted CD8+T cells. Besides, the CKS2 expression was also found to have significant correlations with immunity cycle steps and diverse immune markers in HCC. The high CKS2 expression was confirmed in HCC at both mRNA and protein levels, showing a significant increase compared to normal tissue. Conclusion: CKS2 is a potential prognostic biomarker of HCC and can promote the progression of HCC via its influences on the immune environment. Additionally, a positive correlation between CKS2 and immune markers was observed, highlighting its potential as an immunotherapeutic target. Keywords: hepatocellular carcinoma, CKS2, tumor immune microenvironment, immune cycle, immune markers, immunomodulators Hepatocellular carcinoma (HCC), accounting for 75–85% of all primary liver cancers, is the sixth most commonly diagnosed cancer. 1,2 In recent years, it has been reported that the morbidity and mortality of liver cancer continue to rise, accompanied by a low five-year relative survival rate. 3 Risks of cancer mainly include hepatitis B or C viral infection, alcoholism, non-alcoholic fatty liver disease, obesity, and metabolic syndrome. 4 Only a small number of patients with early liver cancer benefit from radical treatment, including resection, local ablation, or liver transplantation. 5 For advanced patients, although significant progress has been achieved in multimodal therapy, including radiotherapy, chemotherapy, and targeted therapy, 6–11 the prognosis remains far from satisfactory. Notably, the latest research indicates the potential for immunotherapy as a cure for HCC in the future, 12 and in particular, a revolutionary breakthrough has been obtained for immune-checkpoint inhibitors in the treatment of HCC. 13 However, most patients did not respond well to this treatment. 14 The phenomenon has kindled our interest in studying the underlying molecular mechanism that regulates tumor immunotherapy responses and immune microenvironments. Therefore, searching for new prognostic biomarkers and underlying targets for immune-related therapy is important. The cyclin-dependent kinase regulatory subunit (CKS) family consists of two members: CKS1 and CKS2. They are members of highly conserved small (9 KDa) cyclin-dependent kinase (CDK)-binding proteins which are indispensable components in cell cycle regulation. 15,16 Growing evidence has shown the over-expression of CKS2 in diverse tumors, such as colon, breast, and cholangiocarcinoma, 17–19 and the involvement of CKS2 in the progression of tumors. Furthermore, it has been shown that the high expression of this gene in adrenocortical carcinoma and lung adenocarcinoma not only accelerates tumor growth, but also influences immune infiltration and controls the immune m -Abstract Truncated-
oncology